Dentons
We only have limited information for this firm. Consider the following firms which have provided more information:
Jointly led by the ‘attentive, extremely professional’ Jean-Marc Grosperrin, Julien Le Guyader, and Anne-Laure Marcerou, the team at Dentons handles the full gamut of issues in life sciences for its diverse client list, including Panasonic, Pfizer, and Laboratoires Servier. Grosperrin is particularly adept at advising global pharma corporations on domestic and cross-border M&A and private equity transactions, while Marcerou is noted for her deep knowledge of the structuring and negotiation of transactions involving biotech and medtech companies. Le Guyader regularly handles market access mandates and issues concerning international tax law. Having joined the team in February 2023 from Dechert LLP, Jessica Garestier exhibits vast regulatory expertise, particularly in relation to market access, promotion, and health product compliance. Pascale Poupelin is a key name of note within the practice, particularly for market access matters.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘Multidisciplinary and international team. Involved, professional and responsive.’
‘Jean-Marc Grosperrin, very attentive, extremely professional and always able to make himself available.’
Abbreviated data is displayed for this firm.
Key clients
- Panasonic
- Adare Pharmaceuticals
Abbreviated data is displayed for this firm.
Work highlights
- Advising Laboratoires Théa on several matters, including the purchase of R&D assets, the conclusion of a licensing-in agreement with an equity stake in the licensor, and the participation in a financing round in an innovative company.
- Advised Asabys Partners on the investment by its fund SAHII II (Sabadell Asabys Healthcare Innovation Investments II) in Gradient Denervation Technologies, a Paris-based medical device company developing a minimally invasive solution for the treatment of heart failure patients with pulmonary hypertension, as part of its Series A of €20m.
Abbreviated data is displayed for this firm.